U.S. FDA gives nod to first generic version of Eliquis tablets
Category: #health  By Mateen Dalal  Date: 2019-12-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

U.S. FDA gives nod to first generic version of Eliquis tablets

The U.S. FDA (Food and Drug Administration) has reportedly made headlines after it recently approved the first generic versions of Eliquis (apixaban) tablets in the U.S. The generic tablets are formulated to decrease the risk of stroke and systemic embolism with nonvalvular atrial fibrillation (AFib) patients.

These tablets are indicated for the prophylaxis of DVT (deep vein thrombosis) which may lead to PE (pulmonary embolism) in patients who have undergone knee or hip replacement surgery. They are also indicated for PE and DVT treatment to reduce the risk of recurrent PE and DVT following initial therapy. 

According to Janet Woodcock, M.D., Director at FDA’s Center Drug Evaluation and Research, said that the approval of the first generic versions of Eliquis is an example of how FDA’s generic drug program gives better access to safe, high quality and low-cost medicines. Woodcock added that this is the first generic approval of a direct oral anticoagulant.

Apparently, addressing generic drug development challenges and promoting generic drug competition is a vital part of the FDA’s Drug Competition Action Plan. Under this program, the agency is helping patients by giving access to affordable drugs. The approval was granted to Mylan Pharmaceuticals Inc. and Micro Labs Ltd, said the agency.

Meanwhile, reports cite that sales of Apixaban, which was co-developed by Bristol-Myers and Pfizer, rose around 22% to USD 1.93 billion and made up around 30% of the total revenue of Bristol-Myers in the last reported quarter. 

For the uninitiated, atrial fibrillation (AFib) is a heart rhythm issue that can potentially cause blood clots. According to CDC, between 2.7 million and 6.1 million people in the U.S. suffer from atrial fibrillation. Many of its patients use anti-clotting or anticoagulants drugs to reduce its risk.

Source Link - https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-eliquis

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Saepio, Echoworx partner to deliver Next-Gen security solutions
Saepio, Echoworx partner to deliver Next-Gen security solutions
By Mateen Dalal

Saepio Information Security, a market leader in statement encryption and cloud-based email, has reportedly announced its collaboration with Echoworx to offer next-generation safe delivery of sensitive and secret information to any email receiver...

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...